Revolution Medicines (RVMD) Preferred Stock Liabilities (2018 - 2019)
Revolution Medicines' quarterly Preferred Stock Liabilities came in at $305.1 million in Q4 2019, up 48.77% year-on-year from $205.1 million in Q4 2018, and little changed quarter-over-quarter from $305.1 million in Q3 2019.
Revolution Medicines has reported Preferred Stock Liabilities for 2 years, with the latest figure at $305.1 million in Q4 2019.
- For the quarter ending Q4 2019, Preferred Stock Liabilities rose 48.77% year-over-year to $305.1 million; the trailing twelve-month figure through Dec 2019 stood at $305.1 million (up 48.77% YoY), and the FY2019 full-year result was $305.1 million, up 48.77% from the prior year.
- Preferred Stock Liabilities for Q4 2019 stood at $305.1 million, roughly flat from $305.1 million in the prior quarter.
- The five-year high for Preferred Stock Liabilities was $305.1 million in Q3 2019, with the low at $205.1 million in Q4 2018.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2019 | 305.11 Mn |
| Sep 30, 2019 | 305.11 Mn |
| Jun 30, 2019 | 295.02 Mn |
| Mar 31, 2019 | 205.08 Mn |
| Dec 31, 2018 | 205.08 Mn |